Security
Apyx Medical Corporation Common Stock · APYX
APYXNASDAQCommon stockCurrentCIK 719135Updated Oct 6, 2026
Name history
BOVIE MEDICAL CORP · through Jan 2, 2019BOVIE MEDICAL Corp · through Jan 2, 2019AN CON GENETICS INC · through Jan 13, 1999
APYX price & chart
Loading TradingView…
NASDAQ:APYX on TradingView ↗In the news
Apyx Medical Corporation to Release Second Quarter of Fiscal Year 2026 Financial Results on August 6, 2026 ↗
Recent filings
Other Events
Items 8.01, 9.01
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements · Submission of Matters to a Vote of Security Holders
Items 5.02, 5.07, 9.01
10-Q filing
Results of Operations and Financial Condition
Items 2.02, 9.01
Other Events
Items 8.01, 9.01
Show 5 more recent filings
Financials
FY 2025 · USDSource
Source
Source
Source
Source
balance sheet · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| ASSETS | ||||
| AssetsUSD | 66,840,000Source | 64,842,000Source | 79,240,000Source | 51,775,000Source |
| Property, Plant and Equipment, NetUSD | 2,371,000Source | 1,987,000Source | 1,915,000Source | 6,761,000Source |
| Current assets: | ||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 31,740,000Source | 31,741,000Source | 43,652,000Source | 10,192,000Source |
| Accounts Receivable, after Allowance for Credit Loss, CurrentUSD | 16,776,000Source | 15,480,000Source | 14,023,000Source | 10,602,000Source |
| Inventory, NetUSD | 8,602,000Source | 7,564,000Source | 9,923,000Source | 11,797,000Source |
| Assets, CurrentUSD | 58,471,000Source | 56,440,000Source | 70,362,000Source | 42,972,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | 1,353,000Source | 1,655,000Source | 2,734,000Source | 2,737,000Source |
| Operating Lease, Right-of-Use AssetUSD | 4,218,000Source | 4,703,000Source | 5,162,000Source | 710,000Source |
| Other Assets, NoncurrentUSD | 1,752,000Source | 1,664,000Source | 1,732,000Source | 1,217,000Source |
| LIABILITIES AND EQUITY | ||||
| LiabilitiesUSD | 52,009,000Source | 50,507,000Source | 52,318,000Source | 13,982,000Source |
| Stockholders’ equity: | ||||
| Preferred Stock, Value, IssuedUSD | 0Source | 0Source | 0Source | 0Source |
| Common Stock, Value, IssuedUSD | 42,000Source | 38,000Source | 35,000Source | 35,000Source |
| Additional Paid in CapitalUSD | 103,620,000Source | 92,083,000Source | 81,114,000Source | 73,282,000Source |
| Retained Earnings (Accumulated Deficit)USD | -89,122,000Source | -77,911,000Source | -54,448,000Source | -35,735,000Source |
| Stockholders' Equity Attributable to ParentUSD | 14,540,000Source | 14,210,000Source | 26,701,000Source | 37,582,000Source |
| Liabilities and EquityUSD | 66,840,000Source | 64,842,000Source | 79,240,000Source | 51,775,000Source |
| Current liabilities: | ||||
| Liabilities, CurrentUSD | 11,700,000Source | 10,721,000Source | 12,740,000Source | 11,850,000Source |
| Operating Lease, Liability, CurrentUSD | 407,000Source | 335,000Source | 347,000Source | 216,000Source |
| Accounts Payable, CurrentUSD | 3,058,000Source | 2,615,000Source | 2,712,000Source | 2,669,000Source |
| Operating Lease, Liability, NoncurrentUSD | 4,051,000Source | 4,483,000Source | 4,896,000Source | 470,000Source |
| Other Liabilities, NoncurrentUSD | 347,000Source | 259,000Source | 198,000Source | 181,000Source |
| Stockholders' Equity Attributable to Noncontrolling InterestUSD | 291,000Source | 125,000Source | 221,000Source | 211,000Source |
| Additional Financial Items | ||||
| Accrued Liabilities, CurrentUSD | 8,214,000Source | 7,751,000Source | — | 8,928,000Source |
| Deferred Tax Liabilities, NetUSD | 1,307,000Source | 1,359,000Source | — | — |
| Long-term Debt, Excluding Current MaturitiesUSD | 34,849,000Source | 33,893,000Source | 33,185,000Source | — |
cash flow · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Cash flows from operating activities: | ||||
| Net Income (Loss), Including Portion Attributable to Noncontrolling InterestUSD | -11,105,000Source | -23,559,000Source | -18,850,000Source | -23,278,000Source |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||
| Depreciation, Depletion and AmortizationUSD | 655,000Source | 599,000Source | 692,000Source | 890,000Source |
| Share-based Payment Arrangement, Noncash ExpenseUSD | 2,001,000Source | 4,013,000Source | 5,114,000Source | 6,697,000Source |
| Changes in operating assets and liabilities: | ||||
| Increase (Decrease) in Accounts ReceivableUSD | 1,318,000Source | 2,035,000Source | 3,574,000Source | -1,918,000Source |
| Increase (Decrease) in InventoriesUSD | 1,074,000Source | -2,263,000Source | -1,459,000Source | 5,568,000Source |
| Increase (Decrease) in Accounts PayableUSD | 355,000Source | -63,000Source | 25,000Source | 67,000Source |
| Deferred Income Tax Expense (Benefit)USD | — | -4,254,000Source | -4,375,000Source | -5,100,000Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | -8,001,000Source | -18,047,000Source | -5,249,000Source | -20,280,000Source |
| Cash flows from investing activities: | ||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | -1,114,000Source | -722,000Source | 6,734,000Source | -1,010,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | 1,114,000Source | 722,000Source | 533,000Source | 1,010,000Source |
| Cash flows from financing activities: | ||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | 9,580,000Source | 6,745,000Source | 32,166,000Source | 217,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | -1,000Source | -11,911,000Source | 33,460,000Source | -20,678,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | — | — | 43,652,000Source | 10,192,000Source |
| Supplemental disclosure of cash flow information: | ||||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | 4,636,000Source | 4,746,000Source | 1,935,000Source | 15,000Source |
| Income Taxes Paid, NetUSD | 258,000Source | 382,000Source | — | — |
| Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | — | 113,000Source | -191,000Source | 395,000Source |
| Additional Financial Items | ||||
| Share-based Payment Arrangement, ExpenseUSD | 2,001,000Source | 4,013,000Source | 5,114,000Source | 6,697,000Source |
| DepreciationUSD | 700,000Source | 600,000Source | 700,000Source | 700,000Source |
| Gain (Loss) on Disposition of Property Plant Equipment, Excluding Oil and Gas Property and Timber PropertyUSD | — | — | — | -75,000Source |
| Gain (Loss) on Disposition of Property Plant EquipmentUSD | -19,000Source | -13,000Source | 2,531,000Source | — |
| Gain (Loss) on Extinguishment of DebtUSD | — | 0Source | -3,088,000Source | — |
| Income Tax Expense (Benefit)USD | 270,000Source | 252,000Source | -2,432,000Source | 367,000Source |
| InterestExpenseNonoperatingUSD | 5,589,000Source | 5,907,000Source | — | — |
| Inventory Write-downUSD | 341,000Source | 163,000Source | — | — |
| Investment Income, InterestUSD | 1,108,000Source | 1,606,000Source | — | — |
| Net Income (Loss) Attributable to ParentUSD | -11,211,000Source | -23,463,000Source | -18,713,000Source | -23,184,000Source |
| Net Income (Loss) Attributable to Noncontrolling InterestUSD | 106,000Source | -96,000Source | -137,000Source | -94,000Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | -11,211,000Source | -23,463,000Source | -18,713,000Source | — |
| Nonoperating Income (Expense)USD | -4,389,000Source | -4,462,000Source | — | — |
| Operating ExpensesUSD | 39,490,000Source | 48,205,000Source | 53,710,000Source | 52,693,000Source |
| Other Nonoperating Income (Expense)USD | — | -161,000Source | -4,023,000Source | 651,000Source |
| Other Operating Income (Expense), NetUSD | 92,000Source | -161,000Source | 622,000Source | 509,000Source |
| Proceeds from Issuance of Long-term DebtUSD | — | 0Source | 43,474,000Source | — |
| Proceeds from Noncontrolling InterestsUSD | 60,000Source | 0Source | 147,000Source | 0Source |
| Proceeds from Stock Options ExercisedUSD | 488,000Source | 0Source | 86,000Source | — |
| Revenue from Contract with Customer, Including Assessed TaxUSD | 52,844,000Source | 48,102,000Source | — | — |
income statement · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Total RevenueUSD | 52,844,000Source | 48,102,000Source | 52,349,000Source | 44,510,000Source |
| Cost of RevenueUSD | 19,800,000Source | 18,742,000Source | 18,590,000Source | 15,379,000Source |
| Selling, General and Administrative ExpenseUSD | 15,803,000Source | 18,858,000Source | 22,198,000Source | 20,484,000Source |
| Operating Income (Loss)USD | -6,446,000Source | -18,845,000Source | -17,259,000Source | -23,562,000Source |
| Other Nonoperating Income (Expense)USD | — | -161,000Source | -4,023,000Source | 651,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | -10,835,000Source | -23,307,000Source | -21,282,000Source | -22,911,000Source |
| Income Tax Expense (Benefit)USD | 270,000Source | 252,000Source | -2,432,000Source | 367,000Source |
| Net Income (Loss) Attributable to Noncontrolling InterestUSD | 106,000Source | -96,000Source | -137,000Source | -94,000Source |
| Net Income (Loss) Attributable to ParentUSD | -11,211,000Source | -23,463,000Source | -18,713,000Source | -23,184,000Source |
| Earnings Per Share, BasicUSD per share | -0.27Source | -0.66Source | -0.54Source | -0.67Source |
| Earnings Per Share, DilutedUSD per share | — | — | -0.54Source | -0.67Source |
| Weighted Average Number of Shares Outstanding, Basicshares | 41,095,000Source | 35,542,000Source | 34,622,000Source | 34,516,000Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | — | — | 34,622,000Source | 34,516,000Source |
| Interest Expense (non-operating)USD | 5,589,000Source | 5,907,000Source | — | — |
| Additional Financial Items | ||||
| Current Income Tax Expense (Benefit)USD | 270,000Source | 252,000Source | -2,432,000Source | 367,000Source |
| Gross ProfitUSD | 33,044,000Source | 29,360,000Source | 33,759,000Source | 29,131,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, DomesticUSD | -13,855,000Source | — | — | — |
| Interest ExpenseUSD | — | — | 2,478,000Source | 15,000Source |
| Interest Income, OperatingUSD | — | — | 921,000Source | 157,000Source |
| Investment Income, InterestUSD | 1,108,000Source | 1,606,000Source | — | — |
| Labor and Related ExpenseUSD | 14,011,000Source | 17,353,000Source | — | — |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | -11,211,000Source | -23,463,000Source | -18,713,000Source | — |
| Nonoperating Income (Expense)USD | -4,389,000Source | -4,462,000Source | — | — |
| Operating ExpensesUSD | 39,490,000Source | 48,205,000Source | 53,710,000Source | 52,693,000Source |
| Other ExpensesUSD | 34,428,000Source | 43,659,000Source | — | — |
| Other Operating Income (Expense), NetUSD | 92,000Source | -161,000Source | 622,000Source | 509,000Source |
| Research and Development ExpenseUSD | 3,373,000Source | 5,080,000Source | 4,844,000Source | 4,544,000Source |
| Revenue from Contract with Customer, Including Assessed TaxUSD | 52,844,000Source | 48,102,000Source | — | — |
Filing attachments
ex99-1.htm · 8-K · 2025-11-19
EX-99.1 4 ex99-1.htm EX-99.1 Exhibit 99.1 Apyx Medical Corporation Announces Proposed Public Offering of Common Stock CLEARWATER FL, November 17, 2025 - Apyx Medical Corporation (Nasdaq: APYX) (the “Company” or “Apyx Medical”) the leader in surgical aesthetics marketed and sold as Renuvion® and the AYON Body Contouring System™ (AYON), today announced that it is commencing an underwritten public offering of shares of its common stock (or common stock equivalents). The offering is subject to…
Read attachment ↗ex99-2.htm · 8-K · 2025-11-19
EX-99.2 5 ex99-2.htm EX-99.2 Exhibit 99.2 Apyx Medical Corporation Announces Pricing of $10 Million Public Offering of Common Stock CLEARWATER FL, November 18, 2025 - Apyx Medical Corporation (Nasdaq: APYX) (the “Company” or “Apyx Medical”) the leader in surgical aesthetics marketed and sold as Renuvion® and the AYON Body Contouring System™ (AYON), today announced the pricing of its previously announced underwritten public offering of 2,762,431 shares of its common stock at a public offeri…
Read attachment ↗